VWD is a rare hereditary disease caused by congenital quantitative loss and/or qualitative abnormalities of VWF5). VWD is transmitted mainly by autosomal dominant inheritance and partly by autosomal recessive inheritance12). The frequency of VWD varies depending on the population being studied and the criteria used to diagnose the condition. According to estimates, the overall frequency of VWD is approximately 1% in the general population13-15). However, many VWD cases are asymptomatic and may not be diagnosed. The frequency of VWD presenting with bleeding symptoms is generally low, with some estimates suggesting that it is approximately 1% (1 per 10,000)2). In adolescent women with heavy menstrual bleeding, up to 20% of the causes include coagulation disorders, and 5-36% of those are reported to be VWD4,16,17). Women with type 2A VWD, as in this case, usually develop severe bleeding symptoms, including excessive menstrual bleeding requiring blood transfusions and ovarian bleeding after puberty.
VWD is classified into three categories, Types 1, 2, and 3, based on VWF activity, VWF antigen levels, and multimer formation results3). Type 1 has qualitatively normal but quantitatively decreased VWF, accounting for approximately 70% of the VWD cases. Type 2 is due to qualitative abnormalities in VWF and accounts for approximately 25% of VWD. These are further classified into four types: 2A, 2 B, 2M, and 2N. Type 2A accounts for 10-20% of VWD cases and is the most common Type 2 subtype. The pathophysiology is the consumption of macromolecular multimers due to increased binding of abnormal VWF to platelet glycoprotein lb. Type 3, although a rare form of VWD, is an autosomal recessive trait of VWF deficiency, which causes severe submucosal, subcutaneous, and intra-articular hemorrhages.
The basis of VWD treatment is hemostasis at the time of bleeding and prophylaxis during hemostasis by correcting the decrease in VWF and Factor VIII. The main therapeutic agents are desmopressin acetate (DDAVP [1-desamino-8-D-arginine vasopressin]) and VWF-containing concentrate. Tranexamic acid, an antifibrinolytic solvent, is used to treat bleeding from mucous membranes with high fibrinolytic activity or to prevent rebleeding.
DDAVP acts on vasopressin V2 receptors on the membranes of renal collecting tubule cells to exert its antidiuretic effect and is used as a treatment for central diabetes insipidus. It also acts on vasopressin V2 receptors on vascular endothelial cells to promote VWF release from the endothelial cell membrane18). DDAVP is effective for VWD types 1 and 2 but not for type 3. DDAVP is an option for minor bleeding and minor surgery, although repeated dosing weakens its action11).
Hemorrhage prophylaxis is necessary in patients with VWD who undergo surgery. Unlike DDAVP, VWF-containing concentrates can be used in many VWD patients undergoing surgery. The recommended dosage and duration of administration of VWF-containing concentrates depends on the extent of surgery. However, many criteria are empirical, and the guidelines do not specifically address surgery for uterine cavity lesions11,12,19).
To the best of our knowledge, there have been no case reports of delayed bleeding after hysteroscopic surgery for intrauterine lesions in women with VWD. In this case, the hysteroscopic procedure time was less than 30 min, and it was classified as a minor surgery;however, considering the risk of bleeding, a VWF/pd-FVIII concentrate instead of DDAVP was used for hemorrhage prophylaxis. According to the guidelines, the recommended duration of use of VWF-containing concentrates during minor surgery is 1-5 days, although a longer or shorter period may be considered in each case11,12,19). In this case, the VWF/pd-FVIII concentrate was used for 3 days during the perioperative period;however, bleeding from the uterus was observed on postoperative day 6. Although the cause of rebleeding is unknown, additional DDAVP or tranexamic acid may have been required following administration of the VWF/pd-FVIII concentrate after discharge.
Hemostasis for bleeding from the vessel wall consists of the interaction between the vessel endothelium and platelets, and the coagulation cascade. In reproductive-aged women, the hemostatic mechanism for bleeding from the uterine lumen is essentially the same as that for blood vessels in other organs;however, it is controlled by tissue factor (TF) and ovarian steroid hormones20). The uterine endometrium undergoes repeated proliferation and shedding during the menstrual cycle, and is classified into proliferative, secretory, and menstrual phases21). During the proliferative phase, tissue plasminogen activator (t-PA) in the uterine endometrium, which enhances the fibrinolytic system, is upregulated by estrogen20). During the secretory phase, progesterone increases the expression of TF and plasminogen activator inhibitor (PAI-1), which inhibits the conversion of plasminogen to plasmin in the uterine endometrium. Regulation of the expression of these factors related to hemostasis in the uterine endometrium by ovarian steroid hormones is important not only to prevent menstrual blood clotting but also to maintain pregnancy20,21).
The hemostatic mechanism after intrauterine lesion excision is also presumed to be influenced by ovarian hormones. When blood vessels are injured by the removal of intrauterine lesions and blood is exposed to endometrial tissue TF, platelets are activated and cooperate with VWF to aggregate on the vessel wall, resulting in primary hemostasis. A cascade of coagulation factors converts fibrinogen to fibrin, thereby completing secondary hemostasis. In the present case, the patient received five courses of GnRH agonist treatment before surgery. Although the actual measurement of ovarian steroid hormones was not obtained in this case, estrogen and progesterone levels were likely low because the effects of GnRH agonists usually last for about a month22). One possibility for post-operative uterine bleeding in this case could be low levels of ovarian steroid hormones. Low progesterone levels may have resulted in low TF and PAI-1 expression in the endometrium, and secondary hemostasis with coagulation factors may have been inadequate. In addition, the amount of t-PA may have increased in the endometrium and the fibrinolytic activity was enhanced20,21). Taken together, delayed hemostasis due to low ovarian steroid hormone levels and high fibrinolysis activity may have contributed to the bleeding on postoperative day 6, despite the use of VWF-containing concentrate to prevent postoperative bleeding in this patient.
During the removal of intrauterine lesions in patients with VWD, a prolonged low estrogen status with preoperative GnRH agonist administration may be a risk factor for postoperative bleeding. For surgery of intrauterine lesions in patients with VWD, it may be better to avoid preoperative administration of hormonal agents or, if administered, agents, such as GnRH antagonists or progestins that lead to a rapid recovery in estrogen levels after administration is discontinued, should be used.
GnRH agonist was used for excessive menstruation due to VWD and as a preoperative medication for endometrial polyps, enabling menstruation cessation and improving the visual field during surgery. However, the use of GnRH agonist is associated with an increase in estrogen around 2 weeks after administration, known as a “flare-up” effect, which may cause irregular genital bleeding. When using GnRH agonists to cease menstruation during chemotherapy for malignant hematologic diseases, concurrent administration of progestin is carried out both to prevent flare-ups and to stop bleeding, with favorable outcomes reported23). Considering the risk of irregular bleeding, the currently available oral GnRH antagonist may be suitable for preoperative administration since it does not cause a flare-up. Future studies on preoperative medication before intrauterine surgery in patients with coagulopathy may be warranted.
We prioritized coagulation factor products for postoperative rebleeding, but mechanical compression with an intrauterine balloon is also an option. It is effective for primary heavy bleeding during hysteroscopic surgery. In the present case, the patient was infertile, which was the reason why we did not choose the intrauterine balloon method of compression for delayed postoperative rebleeding. Because repeated intrauterine manipulation increases the risk of intrauterine adhesions24), medical treatment with the use of coagulation factor preparations was given priority. If bleeding persisted despite the use of coagulation factor preparations, intrauterine balloon compression was the next option. A two-tiered approach using coagulation factor products and mechanical compression is ideal for rebleeding after hysteroscopic surgery in patients with coagulation abnormalities.
In conclusion, when performing resection for intrauterine lesions in women with VWD, there is a risk of rebleeding a few days after surgery, even with bleeding prophylaxis, according to the guidelines. As the hemostatic mechanism of the endometrium is affected by ovarian steroid hormones, delayed postoperative bleeding should be considered when preoperative hormone therapy is used.